RV
RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.
$0.6839
-10.01%
No data for this timeframe.
Vol
Analyst ConsensusStrong Buy (82%)
Inst. Holders17 funds
Inst. Value$572.7K
SEC Reports4
Press Releases3
Recent Activity
May 18, 2026
earnings_calendar
RVPH Q1 2026 Earnings Scheduled — 2026-05-18
May 13, 2026
SEC
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/sh
PRESS-RELEASE — Impact 7/10
May 13, 2026
SEC
Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the minimum $1.00 bid pr
8-K — Impact 8/10
Apr 15, 2026
SEC
Reviva Pharmaceuticals announced a $10 million financing completed on March 20, 2026, boosting its cash position to appr
8-K — Impact 5/10
Mar 30, 2026
Press
Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2
Impact 6/10
Mar 19, 2026
Press
Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of common stock and accompa
Impact 6/10
Mar 18, 2026
Insider
Bhat Laxminarayan was granted 109,150 shares
President and CEO
Mar 18, 2026
Insider
Prabhu Narayan was granted 40,925 shares
Chief Financial Officer
Price Targets
$25.00
+3555.5% upside
Strong Buy
Current $0.6839
Low $5.00
Median $30.00
High $40.00
3 analysts
$5.00
$40.00
Analyst Ratings
2Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 8, 2026 | Maxim Group | DOWNGRADE | Buy → Hold |
| Mar 31, 2026 | Roth Capital | MAINTAIN | Buy → Buy |
| Mar 30, 2026 | Alliance Global Partners | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | D. Boral Capital | DOWNGRADE | Buy → Hold |
| Jan 5, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.41 ▲ +59.1% | $-0.41 — $-0.41 | 83% YoY | 1 |
| Next Q | $-0.36 ▼ -13.7% | $-0.36 — $-0.36 | 70% YoY | 1 |
| Current FY | $-1.60 ▼ -15.9% | $-1.60 — $-1.60 | 71% YoY | 1 |
| Next FY | $-1.90 ▼ -100.7% | $-1.90 — $-1.90 | -19% YoY | 1 |
Latest Reports
BEARISH
PRESS-RELEASE
7/10
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/sh
May 13, 2026
BEARISH
8-K
8/10
Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the minimum $1.00 bid pr
May 13, 2026
MIXED
Press
6/10
Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $366.7K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $85.8K | — |
| RENAISSANCE TECHNOLOGIES LLC | $31.4K | — |
| VANGUARD FIDUCIARY TRUST CO | $23.1K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 18, 2026 | Bhat Laxminarayan | A | $0.00 |
| Mar 18, 2026 | Prabhu Narayan | A | $0.00 |
17 institutional holders with $572.7K total value (802,929 shares) as of 2026-Q1. Top holders: ROYAL, SUSQUEHANNA, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 75 | $0.00 | 0.0% | — |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 502,300 | $366.7K | 64.0% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 117,568 | $85.8K | 15.0% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 43,002 | $31.4K | 5.5% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 31,598 | $23.1K | 4.0% | — |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 25,500 | $18.6K | 3.3% | — |
| 7 | STATE STREET CORP | 19,160 | $14.0K | 2.4% | — |
| 8 | BlackRock, Inc. | 18,582 | $13.6K | 2.4% | — |
| 9 | TWO SIGMA INVESTMENTS, LP | 10,715 | $7.8K | 1.4% | — |
| 10 | MORGAN STANLEY | 8,530 | $6.2K | 1.1% | — |
| 11 | Vanguard Global Advisers, LLC | 3,115 | $2.3K | 0.4% | — |
| 12 | GROUP ONE TRADING LLC | 3,109 | $2.3K | 0.4% | — |
| 13 | TD Waterhouse Canada Inc. | 625 | $498.00 | 0.1% | — |
| 14 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 470 | $343.00 | 0.1% | — |
| 15 | WELLS FARGO & COMPANY/MN | 150 | $109.00 | 0.0% | — |
| 16 | HRT FINANCIAL LP | 18,423 | $13.00 | 0.0% | — |
| 17 | DANSKE BANK A/S | 7 | $5.00 | 0.0% | — |
2 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Bhat Laxminarayan | President and CEO | AWARD | 109,150 | — | — |
| Mar 18, 2026 | Prabhu Narayan | Chief Financial Officer | AWARD | 40,925 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 6.3/10.
BEARISH
PRESS-RELEASE
7/10
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago
May 13, 2026
BEARISH
8-K
8/10
Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the
May 13, 2026
NEUTRAL
8-K
5/10
Reviva Pharmaceuticals announced a $10 million financing completed on March 20, 2026, boosting its c
Apr 15, 2026
NEUTRAL
8-K
5/10
Reviva Pharmaceuticals Holdings is implementing a 1-for-20 reverse stock split effective March 9, 20
Mar 5, 2026
MIXED
6/10
Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M com
Mar 30, 2026
BEARISH
6/10
Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of comm
Mar 19, 2026
NEUTRAL
4/10
Reviva Pharmaceuticals (RVPH) announced plans for a public offering of common stock and warrants, wi
Mar 18, 2026
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 2 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$25.00 mean target
+3555.5% upside
Strong Buy (3.00)
$5.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $0.6839 |
| Target Low | $5.00 |
| Target Mean | $25.00 |
| Target Median | $30.00 |
| Target High | $40.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.41 | $-0.41 | $-0.41 | 82.9% | +59.1% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.36 | $-0.36 | $-0.36 | 70.0% | -13.7% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.60 | $-1.60 | $-1.60 | 70.8% | -15.9% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.90 | $-1.90 | $-1.90 | -18.8% | -100.7% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.410 | |
| 7d ago | $-0.270 | -0.140 |
| 30d ago | $-1.003 | +0.593 |
| 60d ago | $-0.850 | +0.440 |
| 90d ago | $-0.850 | +0.440 |
6 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 8, 2026 | Maxim Group | DOWNGRADE | Buy | Hold |
| Mar 31, 2026 | Roth Capital | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | Alliance Global Partners | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Jan 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 8 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
May 18, 2026
earnings_calendar
RVPH Q1 2026 Earnings Scheduled — 2026-05-18
May 13, 2026
earnings
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
<p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and
May 13, 2026
earnings_calendar
RVPH Q1 2026 Earnings Scheduled — 2026-05-13
Apr 15, 2026
other
Reviva Announces Letter to Shareholders
<p align="justify">CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Compan
Mar 30, 2026
earnings
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
<p align="center"><em>- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submis
Mar 23, 2026
earnings_calendar
RVPH Q4 2025 Earnings After Market Close — 2026-03-23
Mar 23, 2026
short_volume
Short Volume: RVPH — 78.3% short (0.6M / 0.7M)
Short: 559,958 | Exempt: 375 | TRF Vol: 715,223 | Short Ratio: 78.3% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
offering
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
<p align="justify" style="padding-left:0pt;">CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RV
Mar 18, 2026
offering
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
<p align="justify" style="padding-left:0pt;">CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RV